ren shen bai du wan (Ginseng & Mentha Extract)

Primarily used for strengthening the body resistance and releasing Early-Stage Exterior Disorders due to invasion of Exterior Wind-Cold-Damp. In modern clinic, it is applicable to Common Cold; Influenza; Malaria; Early Stage Dysentery; Early Stage Measles; Suppurative Infections.

Product label: Ginseng & Mentha Extract
Chinese common name: Ren Shen Bai Du Wan
Packing: 200 concentrated pills / bottle
Manufactured by Lanzhou Traditional Herbs, China

Ingredients:
Bupleurum root
Ligusticum wallichii rhizome
Peucedanuma root
Asian ginseng root
Platycodon root
Notopterygium root & rhizome
Pubescent angelica root
Poria sclerotium
Tangerine rind or unripe fruit
Chinese mint aboveground parts

Actions: Replenishing qi and releasing exterior syndrome, expelling cold and dampness.

Indications: It is indicated for qi deficiency due to attack by exogenous pathogenic factors, marked by aversion to cold, fever, headache, aching body, no perspiration, nasal obstruction, cough with whitish sputum, chest distress, pale tongue with whitish fur, superficial and weak pulse. It is applicable to common cold, influenza, bronchitis, allergic dermatitis, urticaria, eczema, sores, and ulcer, etc., which have the above symptoms and belong to qi deficiency due to exogenous wind, cold and dampness.*

Directions: Take 8 pills each time, 3 times a day.
Caution: Do not use during pregnancy.

*These statements have not been evaluated by the Food & Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

通用名称：人参败毒丸
汉语拼音：ren shen bai du wan
包装规格：每瓶200粒浓缩丸

主要成分：人参、羌活、独活、柴胡、前胡、川芎、枳壳、桔梗、茯苓、甘草、生姜。

功能与主治：益气解表、散风祛湿。用于气虚外感风寒湿邪所致恶寒，发热，无汗，口不渴，头痛，肢体酸痛沉重，乏力，咳嗽，鼻塞流清涕。用于流行性感冒、荨麻疹、湿疹等。

服法与用量：口服，一次8粒，一日3次。
孕妇忌服。只发热不怕冷、口渴大量喝水、舌红少津的阴虚液燥证忌用本药。

人参败毒丸源于宋代的《太平惠民合剂局方》，是由人参、茯苓、前胡、川芎、柴胡、羌活等多种药物组成，益气解表、散风祛湿，常用于正气不足的感冒症状。

现代研究人参败毒丸具有解热，抗炎，镇痛，抗菌作用。

根据其组方功效，临床上还可用于以下多种病症的治疗：1. 顽固性头痛；2. 急性病毒性肝炎；3. 肾病综合症 西医治疗该病常用大剂量皮质激素及免疫抑制剂，易耗伤人体正气。

Tags: heat formula, pills, colds formula, Chinese patent medicine, COVID-19, pandemic